GB201714049D0 - New compounds - Google Patents

New compounds

Info

Publication number
GB201714049D0
GB201714049D0 GBGB1714049.2A GB201714049A GB201714049D0 GB 201714049 D0 GB201714049 D0 GB 201714049D0 GB 201714049 A GB201714049 A GB 201714049A GB 201714049 D0 GB201714049 D0 GB 201714049D0
Authority
GB
United Kingdom
Prior art keywords
new compounds
compounds
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB1714049.2A
Other versions
GB2558975B (en
GB2558975A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chronos Therapeutics Ltd
Original Assignee
Chronos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chronos Therapeutics Ltd filed Critical Chronos Therapeutics Ltd
Priority to GB1714049.2A priority Critical patent/GB2558975B/en
Publication of GB201714049D0 publication Critical patent/GB201714049D0/en
Publication of GB2558975A publication Critical patent/GB2558975A/en
Priority to EP18766021.2A priority patent/EP3676261A1/en
Priority to PCT/GB2018/052479 priority patent/WO2019043407A1/en
Priority to CA3074059A priority patent/CA3074059A1/en
Priority to CN201880071489.8A priority patent/CN111315734B/en
Priority to JP2020512422A priority patent/JP7391012B2/en
Priority to AU2018326734A priority patent/AU2018326734B2/en
Priority to KR1020207008652A priority patent/KR20200066295A/en
Priority to US16/643,420 priority patent/US11660293B2/en
Application granted granted Critical
Publication of GB2558975B publication Critical patent/GB2558975B/en
Priority to IL272952A priority patent/IL272952B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
GB1714049.2A 2017-09-01 2017-09-01 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists Active GB2558975B (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB1714049.2A GB2558975B (en) 2017-09-01 2017-09-01 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
US16/643,420 US11660293B2 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
EP18766021.2A EP3676261A1 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
PCT/GB2018/052479 WO2019043407A1 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CA3074059A CA3074059A1 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN201880071489.8A CN111315734B (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists
JP2020512422A JP7391012B2 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
AU2018326734A AU2018326734B2 (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
KR1020207008652A KR20200066295A (en) 2017-09-01 2018-08-31 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
IL272952A IL272952B2 (en) 2017-09-01 2020-02-27 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1714049.2A GB2558975B (en) 2017-09-01 2017-09-01 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
GB201714049D0 true GB201714049D0 (en) 2017-10-18
GB2558975A GB2558975A (en) 2018-07-25
GB2558975B GB2558975B (en) 2019-01-23

Family

ID=60050731

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1714049.2A Active GB2558975B (en) 2017-09-01 2017-09-01 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

Country Status (1)

Country Link
GB (1) GB2558975B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2713184A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
SG175026A1 (en) * 2009-04-24 2011-11-28 Glaxo Group Ltd 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
EP2275421A1 (en) * 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
WO2012089606A1 (en) * 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) * 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
ES2672732T3 (en) * 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolines / substituted piperidines as orexin receptor antagonists
ITMI20120424A1 (en) * 2012-03-19 2013-09-20 Rottapharm Spa CHEMICAL COMPOUNDS
TWI621618B (en) * 2013-03-13 2018-04-21 比利時商健生藥品公司 Substituted 2-azabicycles and their use as orexin receptor modulators
BR112017004742B1 (en) * 2014-09-11 2022-11-29 Janssen Pharmaceutica Nv SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

Also Published As

Publication number Publication date
GB2558975B (en) 2019-01-23
GB2558975A (en) 2018-07-25

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201700814D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201717530D0 (en) New compounds
GB201714049D0 (en) New compounds
GB201712289D0 (en) New compounds
GB201716374D0 (en) Compounds
GB201716352D0 (en) Compounds
GB201713319D0 (en) Compounds
GB201713318D0 (en) Compounds
GB201702730D0 (en) New compounds
GB201702726D0 (en) New compounds
GB201702725D0 (en) New compounds
GB201702723D0 (en) New compounds